Millendo Therapeutics Share Price

MLND

US60040X1037

Biotechnology & Medical Research

Latest news: Millendo Therapeutics

10/05/23	Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
29/12/22	Millendo Therapeutics, Inc. and Tempest Therapeutics, Inc. Enter into First Amendment to Loan and Security Agreement	CI
30/09/21	Millendo Therapeutics, Inc. Joins Nicholas Maestas as Vice President, Strategy and Finance and It's Principal Financial Officer	CI
25/06/21	Millendo Therapeutics, Inc.(NasdaqCM:MLND) dropped from NASDAQ Composite Index	CI
24/06/21	Tempest Therapeutics Inc. completed the acquisition of Millendo Therapeutics, Inc. in a reverse merger transaction for approximately $180 million.	CI
22/06/21	Millendo Therapeutics : , Tempest Therapeutics Investors Approve Merger Proposals	MT
13/05/21	Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
29/03/21	Millendo Therapeutics, Inc., Tempest Therapeutics Inc. - M&A Call
29/03/21	Millendo Therapeutics : Tempest, Millendo Agree to Merge, Combined Company to List on NASDAQ	MT
29/03/21	Millendo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	CI
28/03/21	Tempest Therapeutics Inc. entered into a definitive agreement and plan of merger to acquire Millendo Therapeutics, Inc. in a reverse merger transaction.	CI
28/01/21	Millendo Therapeutics, Inc. Announces Executive Changes	CI
28/01/21	Millendo Therapeutics, Inc. Plans to Reduce Its Workforce with Majority of Reduction in Personnel Expects to Complete by April 15, 2021	CI

More news

Analysts' recommendations: Millendo Therapeutics

06/01/21	Millendo Therapeutics : Ladenburg Thalmann Downgrades Millendo Therapeutics to Neutral from Buy	MT
06/01/21	Millendo Therapeutics : SVB Leerink Downgrades Millendo Therapeutics to Market Perform From Outperform; Price Target is $2	MT
09/11/20	Millendo Therapeutics : Wedbush Adjusts Price Target for Millendo Therapeutics to $2 From $3, Maintains Neutral Rating	MT

More recommendations

Press Releases: Millendo Therapeutics

23/07/21	TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
16/07/21	Tempest Therapeutics : BUSINESS (Form 8-K)	PU
16/07/21	TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
12/07/21	Tempest Therapeutics : to Participate in William Blair 2021 Biotech Focus Conference	AQ
12/07/21	TEMPEST THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ

More press releases

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MILLENDO THERAPEUTICS	-14.88%	+3.21%	-	-	303M
LONZA GROUP AG	+0.11%	+2.71%	+0.33%	+28.59%	46.28B
IQVIA HOLDINGS INC.	-1.12%	+1.78%	+40.07%	+27.26%	43.85B
REVOLUTION MEDICINES, INC.	-3.04%	-6.29%	+322.27%	+517.36%	40.93B
BEONE MEDICINES AG	-0.74%	+1.25%	+2.32%	+67.94%	39.9B
CELLTRION, INC.	-0.50%	+0.67%	+11.79%	+40.51%	29.5B
MEDPACE HOLDINGS, INC.	-0.46%	+4.22%	+21.99%	+124.21%	17.09B
ASCENDIS PHARMA A/S	-0.97%	-10.17%	-	-	15.55B
EUROFINS SCIENTIFIC SE	-0.57%	+8.12%	+22.15%	+38.93%	15.22B
TEMPUS AI, INC.	-3.14%	+31.91%	-10.60%	-	14.05B
Average	-2.38%	+3.76%	+51.29%	+120.69%	29.15B
Weighted average by Cap.	-1.03%	+1.87%	+64.69%	+130.23%

See all sector performances

Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.

Employees

Sector

Biotechnology & Medical Research

More about the company